Biotest (BIO) AI Stock Analysis

• Market Cap: €1.40B
• Dividend Yield: 0.1%
• Average Volume (3M): 104.00
• Price to Earnings (P/E): 64.1
• Beta (1Y): -0.07
• Revenue Growth: -18.82%
• EPS Growth: -113.85%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 24
• 30 Day Avg. Volume: 104
• PEG Ratio: 1.07
• Price to Book (P/B): 4.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: €43.00 ▲(4.37%Upside)

Biotest's overall stock score is driven primarily by its stable financial position and improved cash flows, despite operational challenges affecting profitability. The technical outlook is neutral with limited momentum, and the valuation remains a significant concern due to the negative P/E ratio. The high dividend yield provides some support but is overshadowed by the valuation risks.

Biotest Business Overview & Revenue Model

Company Description

Biotest AG is a Germany-based biotechnology company specializing in the development and production of plasma protein therapies and biotherapeutic drugs. The company operates primarily in the healthcare sector, focusing on products for clinical immunology, hematology, and intensive care medicine. Biotest's core products include immunoglobulins, clotting factors, and albumin solutions, which are used in treating various life-threatening diseases and conditions.

How the Company Makes Money

Biotest generates revenue through the manufacturing and sale of plasma protein products and biotherapeutic drugs. The company's key revenue streams include sales of immunoglobulins, which are essential for patients with immune deficiencies; clotting factors used for treating hemophilia and other bleeding disorders; and albumin solutions used in intensive care settings. Biotest also engages in research and development activities aimed at expanding its product portfolio and improving existing therapies. Strategic partnerships and collaborations with other pharmaceutical and biotechnology firms can also contribute to its earnings by facilitating market expansion and distribution of its products.

Biotest Financial Statement Overview

Summary

Biotest shows balanced financial performance with a stable balance sheet and improved cash flows. However, there are challenges in maintaining consistent profitability due to operational inefficiencies.

Income Statement

Biotest's income statement shows a mixed performance. Gross Profit Margin improved to 30.82% in the latest year, coupled with a positive Net Profit Margin of 3.63%, indicating moderate profitability. However, the company experienced a significant drop in Gross Profit from the previous year, suggesting volatility in profit generation. Revenue growth from 2023 to 2024 was 6.08%, which is positive but marked by a decline in EBIT and EBITDA margins, indicating rising operational costs or inefficiencies.

Balance Sheet

The balance sheet of Biotest indicates a stable financial position. The Debt-to-Equity Ratio stands at 1.13, reflecting a balanced capital structure. Return on Equity is modest at 4.97%, showing moderate returns to equity holders. The Equity Ratio of 37.00% suggests a strong equity base relative to total assets, enhancing financial stability. However, the increase in total debt over time could pose potential risks if not managed well.

Cash Flow

Biotest's cash flow statements reveal stable cash flow management. Operating Cash Flow to Net Income Ratio is 2.31, indicating strong cash generation relative to net income. Free Cash Flow improved significantly to a positive $32.2 million in 2024 from a negative position in the prior year, suggesting robust cash flow improvement. However, the fluctuation in free cash flow growth over the years denotes potential instability in cash generation capability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	726.20M	684.60M	516.10M	515.60M	484.20M
Gross Profit	223.80M	280.30M	124.90M	80.70M	130.10M
EBITDA	120.40M	179.00M	28.30M	-17.70M	16.00M
Net Income	26.40M	127.00M	-31.60M	-63.30M	-31.40M
Balance Sheet
Total Assets	1.43B	1.41B	1.20B	1.10B	1.13B
Cash, Cash Equivalents and Short-Term Investments	119.50M	118.50M	136.60M	117.50M	89.20M
Total Debt	597.20M	689.80M	574.30M	496.30M	469.10M
Total Liabilities	903.30M	912.00M	831.90M	723.80M	689.70M
Stockholders Equity	530.70M	498.90M	371.10M	380.40M	441.60M
Cash Flow
Free Cash Flow	32.20M	-36.10M	-69.80M	15.70M	-43.70M
Operating Cash Flow	60.90M	-2.70M	-40.50M	33.90M	-16.70M
Investing Cash Flow	-25.70M	1.30M	-37.00M	-23.40M	-14.60M
Financing Cash Flow	-35.40M	-6.80M	89.60M	22.60M	42.00M

Biotest Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 41.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Positive. The current price of 41.2 is below the 20-day moving average (MA) of 41.40, below the 50-day MA of 42.14, and below the 200-day MA of 41.66, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 50.19 is Neutral, neither overbought nor oversold. The STOCH value of 10.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BIO.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EUZ	75 Outperform	€1.38B	40.21	17.48%	0.65%	15.89%	14.62%
EUZ	75 Outperform	€1.38B	40.21	17.48%	0.65%	15.89%	14.62%
Sector *	64 Neutral	€6.40B	20.05	-1.17%	2.13%	0.06%	-43.17%
ILM1	62 Neutral	€322.90M	21.46	2.99%	―	5.62%	-21.87%
ILM1	62 Neutral	€322.90M	21.46	2.99%	―	5.62%	-21.87%
BIO	53 Neutral	€1.40B	64.15	-4.72%	0.10%	-18.82%	-113.85%
FYB	51 Neutral	€514.03M	5.89	-26.06%	―	-10.32%	-250.76%
FYB	51 Neutral	€514.03M	5.89	-26.06%	―	-10.32%	-250.76%
EVT	46 Neutral	€1.28B	―	-20.51%	―	1.50%	-127.76%
EVT	46 Neutral	€1.28B	―	-20.51%	―	1.50%	-127.76%